Jeffrey Lawrence Schwartz Sells 3,890 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Director Jeffrey Lawrence Schwartz sold 3,890 shares of the firm’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $25.18, for a total transaction of $97,950.20. Following the sale, the director owned 7,019 shares in the company, valued at approximately $176,738.42. This represents a 35.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Price Performance

Shares of NASDAQ:KMTS traded down $0.50 during trading on Thursday, reaching $23.57. 310,496 shares of the company’s stock traded hands, compared to its average volume of 240,413. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16. Kestra Medical Technologies, Ltd. has a fifty-two week low of $17.34 and a fifty-two week high of $30.00. The company has a 50-day simple moving average of $25.42 and a 200-day simple moving average of $22.71. The firm has a market cap of $1.38 billion, a PE ratio of -9.74 and a beta of 0.62.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The firm had revenue of $28.64 million for the quarter. As a group, analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.

Institutional Investors Weigh In On Kestra Medical Technologies

Institutional investors and hedge funds have recently modified their holdings of the company. Corient Private Wealth LP increased its stake in Kestra Medical Technologies by 284.2% during the second quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock worth $1,542,000 after purchasing an additional 44,839 shares during the period. California State Teachers Retirement System lifted its holdings in Kestra Medical Technologies by 2,366.0% during the 2nd quarter. California State Teachers Retirement System now owns 686,422 shares of the company’s stock worth $17,463,000 after buying an additional 658,587 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in Kestra Medical Technologies by 6.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock valued at $1,844,000 after buying an additional 5,731 shares during the period. Quantinno Capital Management LP acquired a new stake in shares of Kestra Medical Technologies in the first quarter valued at $431,000. Finally, Sei Investments Co. boosted its holdings in Kestra Medical Technologies by 22.6% in the first quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after purchasing an additional 43,753 shares during the period.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 31st. JPMorgan Chase & Co. began coverage on shares of Kestra Medical Technologies in a report on Monday, August 10th. They issued an “overweight” rating and a $30.00 price objective for the company. Wall Street Zen raised shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Oppenheimer assumed coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating for the company. Finally, BTIG Research restated a “buy” rating and set a $32.00 price target on shares of Kestra Medical Technologies in a report on Wednesday, September 2nd. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Kestra Medical Technologies has a consensus rating of “Hold” and a consensus target price of $28.14.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.